Document Detail

Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease.
MedLine Citation:
PMID:  14632776     Owner:  NLM     Status:  MEDLINE    
The cell surface proteins CD20 and CD52 differ significantly in their structures and are expressed on the majority of B cells. Both circulating CD20 (cCD20) and circulating CD52 (cCD52) have been recently documented in patients with chronic lymphocytic leukaemia. A retrospective study to establish whether cCD20 and/or cCD52 were detectable in patients with lymphoma, and the clinical associations of these soluble antigens if detected, was conducted. cCD20 and cCD52 levels were analysed in a cohort of 65 patients with non-Hodgkin's lymphoma (NHL) and 37 with Hodgkin's disease (HD). Patients with NHL had elevated pretherapy levels of cCD20 and cCD52 compared with normal individuals. Patients with HD had significantly lower than normal pretherapy levels of both cCD20 and cCD52. cCD20 levels were marginally elevated post-therapy in NHL patients while in patients with HD, cCD20 levels remained significantly lower than normal after therapy. Serum cCD52 levels became significantly lower than normal post-therapy in NHL patients, and remained significantly lower than normal in HD patients. No predictive effects were found for pretherapy or post-therapy levels of cCD52 on survival for either cohort of patients. Post-therapy cCD20 levels independently highly correlated with survival in patients with NHL. Prospective evaluation will be required to establish if cCD20 and cCD52 may be used as biomarkers in the diagnosis, prognostic categorization, and monitoring of the clinical course in patients with lymphoma. The clinical significance of circulating antigen in patients receiving monoclonal antibody therapy directed against CD20 and/or CD52 warrants study.
Francis J Giles; Julie M Vose; Kim-Anh Do; Marcella M Johnson; Taghi Manshouri; Gregory Bociek; Philip J Bierman; Susan M O'Brien; Michael J Keating; Hagop M Kantarjian; James O Armitage; Maher Albitar
Related Documents :
3476986 - Plasma-selenium, glutathione peroxidase in erythrocytes and mercury in plasma in patien...
21450986 - Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measur...
18181206 - Huntington's disease phenocopies are clinically and genetically heterogeneous.
7554526 - The pathogenesis of decreased aspartate aminotransferase and alanine aminotransferase a...
23459976 - Gait variability at fast-pace walking speed: a biomarker of mild cognitive impairment?
22279306 - Dysfunctional voiding: a review of the terminology, presentation, evaluation and manage...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  British journal of haematology     Volume:  123     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2003 Dec 
Date Detail:
Created Date:  2003-11-24     Completed Date:  2004-01-23     Revised Date:  2013-11-08    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  850-7     Citation Subset:  IM    
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antigens, CD / blood*
Antigens, CD20 / blood*
Antigens, Neoplasm / blood*
B-Lymphocytes / immunology*
Biological Markers / blood
Enzyme-Linked Immunosorbent Assay / methods
Glycoproteins / blood*
Hodgkin Disease / drug therapy,  immunology*,  mortality
Logistic Models
Lymphoma, Non-Hodgkin / drug therapy,  immunology*,  mortality
Middle Aged
Statistics, Nonparametric
Survival Rate
Treatment Outcome
Grant Support
Reg. No./Substance:
0/Antigens, CD; 0/Antigens, CD20; 0/Antigens, Neoplasm; 0/Biological Markers; 0/CD52 antigen; 0/Glycoproteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Adult T-biphenotypic acute leukaemia: clinical and biological features and outcome.
Next Document:  Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect o...